{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-197961","form_type":"8-K","ticker":"AVD","cik":"0000005981","company_name":"AMERICAN VANGUARD CORP","filed_at":"2024-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.583172+00:00","generated_at":"2026-05-31T10:35:15.203709+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"American Vanguard Q2 EPS -$0.42; cuts FY2024 EBITDA guidance to $40-50M; EPA suspends Dacthal","bullets":["Net sales $128.2M vs $132.8M Q2; Adj EBITDA $6.2M vs $10.7M; EPS $(0.42) vs $(0.04).","FY2024 guidance cut: Adj EBITDA now $40-50M (prev. $60-70M); net sales down 2% to flat (prev. +6-9%).","EPA issued emergency suspension of Dacthal; company had voluntarily paused sales in April 2024.","New credit agreement relaxes EBITDA covenant through Q3 2025; upsizes excluded charges; increases rates at high leverage.","Workforce reduced ~4%; seeking partner for SIMPAS; targeting 15% Adj EBITDA margins by 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-197961","json":"https://secwatch.observer/filing/0001193125-24-197961.json","markdown":"https://secwatch.observer/filing/0001193125-24-197961.md","text":"https://secwatch.observer/filing/0001193125-24-197961.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/5981/000119312524197961/0001193125-24-197961-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/5981/000119312524197961/d796763d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:35:15.203709+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}